/
MDWD
$15.08-$0.11 (-0.72%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$195.2M
13M shares
52-week range
$13.54 – $21.26
20% from low
Exchange
NASDAQ
CS
Borrow rate
1.99%
Moderate
Price (6 mo)
Loading chart…
Change$-13.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $31.8M | $21.8M | $23.8M | $26.5M | $18.7M | $20.2M | $17.0M |
| Cost of revenue | $2.1M | $11.8M | $14.2M | $15.0M | $13.3M | $15.1M | $17.6M | $13.7M |
| Gross profit | $1.3M | $19.9M | $7.5M | $8.8M | $13.2M | $3.6M | $2.6M | $3.3M |
| Gross margin | 38.6% | 62.7% | 34.7% | 36.9% | 49.7% | 19.1% | 13.0% | 19.2% |
| R&D | $4.1M | $5.0M | $7.7M | $10.3M | $10.2M | $7.5M | $8.9M | $14.3M |
| Operating income | −$4.0M | $4.5M | −$8.8M | −$11.2M | −$7.7M | −$15.5M | −$19.4M | −$25.3M |
| EBITDA | −$4.2M | $4.1M | −$7.4M | −$11.4M | −$18.2M | −$4.8M | −$27.9M | −$21.5M |
| Net income | −$1.1M | $5.0M | −$9.2M | −$13.6M | −$19.6M | −$6.7M | −$30.2M | −$23.9M |
| Net margin | -31.1% | 15.6% | -42.3% | -57.0% | -74.0% | -35.9% | -149.5% | -140.8% |
| EPS (diluted) | -0.28 | 1.26 | -2.38 | -3.48 | -3.93 | -0.75 | -3.03 | -2.10 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $24M | $-2.31 | $-2.78–$-2.01 | 5 |
| 2027 | $33M | $-2.13 | $-2.61–$-1.68 | 5 |
| 2028 | $50M | $-1.14 | $-1.50–$-0.93 | 3 |
| 2029 | $109M | $0.62 | $0.58–$0.65 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
www.mediwound.com- Employees
- 121
- IPO / List date
- Mar 20, 2014
Held by traders on TradeandTell
No one on the platform currently holds MDWD.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MDWD as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2022-12-20 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded MDWD yet.
